Compare STRA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | TSHA |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1996 | 2020 |
| Metric | STRA | TSHA |
|---|---|---|
| Price | $85.31 | $6.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $87.00 | $11.63 |
| AVG Volume (30 Days) | 281.8K | ★ 2.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 15.85 | 5.56 |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $997,137,000.00 | $9,773,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | $1,152.42 |
| P/E Ratio | $26.97 | ★ N/A |
| Revenue Growth | ★ 57.23 | 17.28 |
| 52 Week Low | $69.70 | $2.72 |
| 52 Week High | $89.73 | $7.30 |
| Indicator | STRA | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 47.42 |
| Support Level | $77.33 | $5.28 |
| Resistance Level | $88.55 | $6.01 |
| Average True Range (ATR) | 2.32 | 0.33 |
| MACD | 0.36 | -0.03 |
| Stochastic Oscillator | 97.40 | 25.53 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.